α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

被引：46
|
作者：
Ishikawa, Masatomo [1 ]
Hashimoto, Kenji [1 ]
机构：
[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba 2608670, Japan
来源：
CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 02期
关键词：
alpha 7 nicotinic acetylcholine receptors; schizophrenia; smoking; nicotine; P50 auditory evoked potential suppression; agonists; allosteric modulators; VITRO PHARMACOLOGICAL CHARACTERIZATION; POSITIVE ALLOSTERIC MODULATOR; INDUCED COGNITIVE DEFICITS; REPEATED AUDITORY-STIMULI; IN-VIVO CHARACTERIZATION; MIDBRAIN DOPAMINE AREAS; CIGARETTE-SMOKING; P50; SUPPRESSION; PARTIAL AGONIST; DBA/2; MICE;
D O I：
10.2174/138161211795049561
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Accumulating evidence suggests that the alpha 7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of alpha 7 nAChRs in the brain. Some agonists (e. g., DMXB-A and tropisetron) at alpha 7 nAChRs can improve P50 deficits in patients with schizophrenia. Together, these findings indicate that alpha 7 nAChRs are a potential therapeutic target for schizophrenia. Currently, a number of agonists and allosteric modulators at alpha 7 nAChRs are under development as potential therapeutic drugs. In this article, we review recent topics on alpha 7 nAChR agonists and alpha 7 nAChR allosteric modulators as therapeutic drugs for schizophrenia.
引用
收藏
页码：121 / 129
页数：9
相关论文
共 50 条
  • [21] Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology
    Pohanka, Miroslav
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (02) : 2219 - 2238
  • [22] The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
    de Jonge, W. J.
    Ulloa, L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (07) : 915 - 929
  • [23] Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
    Decker, MW
    Meyer, MD
    BIOCHEMICAL PHARMACOLOGY, 1999, 58 (06) : 917 - 923
  • [24] Neuronal nicotinic acetylcholine receptor modulators: Recent advances and therapeutic potential
    Breining, SR
    Mazurov, AA
    Miller, CH
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 3 - 16
  • [25] A PHASE 2 TRIAL OF AN ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST IN SCHIZOPHRENIA
    Freedman, Robert
    Olincy, A.
    Johnson, L.
    Buchanan, R. W.
    Kem, W. R.
    SCHIZOPHRENIA BULLETIN, 2009, 35 : 335 - 335
  • [26] Efficacy of novel α7 nicotinic acetylcholine receptor partial agonists in models of schizophrenia
    King, Dalton
    Cook, Jim
    Iwuagwu, Christiana
    Fang, Haiquan
    Hill, Matthew D.
    Mate, Robert
    McDonald, Ivar M.
    Xie, Kai
    Zusi, F. Christopher
    Easton, Amy
    Lidge, Regina
    Jones, Kelli
    Li, Yu-Wen
    Pieschl, Rick
    Sivarao, Digavalli V.
    Chen, Ping
    Bristow, Linda
    Zaczek, Robert
    Olson, Richard E.
    Macor, John E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [27] Regulatory and structural functioning of α7 nicotinic acetylcholine receptor splice variants in schizophrenia
    Severance, E. G.
    Yolken, R. H.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 304 - 304
  • [28] Stress and the α7 Nicotinic Acetylcholine Receptor
    Hunter, Richard G.
    CURRENT DRUG TARGETS, 2012, 13 (05) : 607 - 612
  • [29] Novel?7 nicotinic acetylcholine receptor modulators as potential antitussive agents
    Mazurov, Anatoly
    Ho, Jenny
    Low, Tiffany
    Hoeng, Julia
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [30] α7 Nicotinic Acetylcholine Receptor May Be a Pharmacological Target for Perioperative Neurocognitive Disorders
    Wei, Penghui
    Lyu, Wenyuan
    Xu, Lin
    Feng, Hao
    Zhou, Haipeng
    Li, Jianjun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345